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The targeting of telomerase and telomere maintenance mechanisms represents a promising therapeutic 
approach for various types of cancer. In this work, we designed a new protocol to screen for and rank the 
efficacy of compounds specifically targeting telomeres and telomerase. This approach used two isogenic 
cell lines containing a circular human artificial chromosome (HAC, lacking telomeres) and a linear HAC 
(containing telomeres) marked with the EGFP transgene: compounds that target telomerase or telomeres 
should preferentially induce loss of the linear HAC but not the circular HAC. Our assay allowed 
quantification of chromosome loss by routine flow cytometry. We applied this dual-HAC assay to rank a 
set of known and newly developed compounds, including G-quadruplex (G4) ligands. Among the latter 
group, two compounds -Cu-ttpy and Pt-ttpy- induced a high rate of linear HAC loss with no significant 
effect on the mitotic stability of a circular HAC. Analysis of the mitotic phenotypes induced by these 
drugs revealed an elevated rate of chromatin bridges in late mitosis and cytokinesis as well as UFB 
(Ultrafine Bridges). Chromosome loss after Pt-ttpy or Cu-ttpy treatment correlated with the induction of 
telomere-associated DNA damage. Overall, this platform enables identification and ranking of 
compounds that greatly increase chromosome mis-segregation rates as a result of telomere dysfunction 










Aneuploidy or an abnormal chromosome number is a common feature of many cancers and is 
often accompanied by an elevated rate of chromosome instability (CIN) (1). Gain or loss of entire 
chromosomes leads to changes in gene copy number and expression levels. Recent findings point to that 
experimentally induced CIN may be a barrier to tumor growth that can be exploited therapeutically (2-5). 
However, drugs that increase CIN beyond the therapeutic threshold are currently limited. Developing 
novel strategies to screen the compounds specifically modulating CIN and to exploit the fitness cost 
associated with excessive aneuploidy is important for the successful treatment of cancer. 
Telomeres - protective caps at the ends of human chromosomes – are potential targets for 
increasing CIN. Telomeres shorten with each successive cell division in normal cells whereas in tumors 
they are continuously elongated by telomerase reverse transcriptase (hTERT). Telomerase is 
overexpressed in 80–95% of cancers and is present at very low levels in normal cells. Because telomerase 
plays a key role in cancer cell proliferation it may serve as a useful target for anticancer therapeutics. 
Inhibition of telomerase in telomerase-positive tumors could potentially lead to a decrease of telomere 
length resulting in CIN, cell senescence and apoptosis.  
Several strategies have been developed for telomerase inhibition based on targeting either hTERT 
or its RNA subunit with small molecule inhibitors or antisense oligonucleotides (6). However, interest in 
their use for therapeutic approaches is diminished by the observation that significant effects on tumor 
growth were obtained only after long-term drug administration required for telomeres to reach a critical 
length.  Such long-term telomerase inhibition has the potential to select for cells expressing the alternative 
lengthening of telomeres (ALT) pathway in which chromosomal ends are maintained by a recombination-
based mechanism (7).   
 The telomeric structure itself offers a potential target for telomere-binding compounds in short-
term treatments (8). Thus, G4 ligands, a class of molecules that are able to interact with G-quadruplex 
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(abbreviated G4) structures formed by the G-rich overhang of telomeric DNA have recently received 
considerable attention (9-11). G4-stabilizing molecules such as Telomestatin, Braco-19, 360A (PDC) and 
RHPS4 can reduce cancer growth by rending telomeres dysfunctional. In contrast to hTERT inhibitors, 
G4 ligands represent a good example of a multimodal class of drugs, able even after a short treatment to 
simultaneously affect multiple targets participating in several distinct pathways (including the complex 
mechanism of gene expression). This simplifies the treatment modalities, improving the selectivity 
against cancer cells and avoiding the selection of ALT cells. Until now there has been no reliable method 
to quantify the effect of different G4 ligands on chromosome instability.     
 In our previous work, we developed a quantitative assay to measure CIN in response to cell 
treatment by different compounds (12). This assay was based on the use of a circular human artificial 
chromosome (HAC) constructed in our lab (13).  The HAC has previously been used for the efficient and 
regulated expression of genes of interest (14) and kinetochore studies (15,16,17). It contains centromeric 
repeats that form a functional centromere/kinetochore allowing its stable inheritance as a nonessential 
chromosome, albeit with a loss rate roughly 10x that of the native chromosomes (15). In order to develop 
a quantitative (“loss of signal”) assay for chromosome mis-segregation, we used a modified HAC 
carrying a constitutively expressed EGFP transgene (12). Cells that inherit the HAC display green 
fluorescence, while cells lacking the HAC do not. This allows the measurement of HAC loss rate by flow 
cytometry, providing a quick and efficient way to screen hundreds of drugs and identify those affecting 
chromosome mis-segregation. The assay was successfully used to rank different anticancer drugs 
according to their effects on chromosome transmission (18). More recently, this HAC-based assay was 
adapted for high-throughput screening of chemical libraries using a fluorescence microplate reader to 
identify compounds that elevate chromosome mis-segregation and drive lethal aneuploidy (19). In the 
modified assay, cells carry the EGFP transgene integrated in the genome and the HAC carries a 
constitutively expressed shRNA against EGFP. Cells display green fluorescence only after loss of the 
HAC (“gain of signal” assay). Using both HAC-based systems we have identified new and potentially 
less toxic agents that selectively elevate CIN in cancer cells.  
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 In the present work, we further modified our HAC-based screening protocol to identify 
compounds specifically targeting telomeres or telomerase. This protocol is based on the use of two 
isogenic cell lines expressing the EGFP transgene: one carrying a circular HAC lacking telomeres and the 
other carrying a linear HAC with telomeres. We hypothesized that compounds specifically inhibiting 
telomerase or other telomere functions would induce loss of the linear HAC but not the circular HAC. 
Our screen included known telomerase inhibitors as well as a set of known and newly developed G4 
ligands. Among this last group, Pt-ttpy and Cu-ttpy (20,21) induced the highest rate of loss of the linear 
HAC. 
Identification of new compounds that greatly increase chromosome mis-segregation rates as a 
result of telomere dysfunction may expedite the development of new therapeutic strategies for cancer. 
 
Materials and Methods 
 
Cell lines and culture 
 
The human fibrosarcoma (HT1080; ATCC® CCL-121™), human colon carcinoma (HCT116; 
(ATCC® CCL-247™) and human osteosarcoma (U2OS; ATCC® HTB-96™) cell lines were obtained 
from the American Type Culture Collection and were authenticated both morphologically and by short 
tandem repeat analysis. All cell lines were tested regularly to confirm lack of mycoplasma infection with 
mycoplasma detection kit PlasmoTest from InvivoGen. 
The human fibrosarcoma HT1080 cells (telomerase positive) harboring either alphoidtetO-HAC-
EGFP or 21ΔqHAC-EGFP were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) 
supplemented with 10% (v/v) tet system-approved fetal bovine serum (FBS, Clontech Laboratories, Inc.) 
at 37°C in 5% CO2. Human colon carcinoma HCT116 cells (telomerase positive) were cultured in 
McCoy’s 5A medium supplemented with 10% FBS at 37oC and 5% CO2. Human osteosarcoma U2OS 
cells (telomerase negative) were cultured in DMEM supplemented with 10% FBS at 37oC and 5% CO2. 
 6 
For chromosome instability experiments, HT1080 cells were grown in blasticidin-containing 
medium to prevent HAC loss prior to treatment with the drugs being tested (both linear and circular 
HACs contain the BS marker). After drug treatment, the cells were cultured in a non-selective medium to 
allow HAC loss, i.e. under conditions when the cells that have lost a HAC are able to grow. For mitotic 
abnormality experiments, the cells were not exposed to blasticidin because the experiments were carried 




Analysis of EGFP expression was performed on a FACS Calibur instrument (BD Biosciences) using 
CellQuest acquisition software and analyzed statistically with FlowJo software. The cells were harvested 
by trypsin-treatment. Intensities of fluorescence were determined by flow cytometry. A minimum of 4 x 
104 cells was analyzed for each cell sample. 
 
Compounds and treatments 
 
23 different compounds were used in our experiments (Supplementary Table S1). Our experiment 
protocol was as follows. HT1080 cells containing a EGFP-HAC were maintained on blasticidin selection 
to select for the presence of the HAC. Approximately 1 × 105 cells were cultured either in the presence or 
absence of blasticidin selection in parallel with a third culture that was exposed to the agent under 
examination to test its effect on EGFP-HAC segregation. The compound concentration applied for 
measuring chromosome instability was adjusted to the LC50 level for each compound (determined using 
a proliferation assay described below). Concentrations of compounds and lengths of treatment are 
presented in Supplementary Table S2. After treatment, the compound was removed by performing three 
consecutive medium washes and the cells were subsequently grown without blasticidin selection for 1–14 
days. At the end of the experiment, cells were collected and analyzed by flow cytometry to detect the 
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proportion of cells that retain EGFP fluorescence. This served as a measure of EGFP-HAC stability 
following compound treatment. For each compound, the experiments on measuring EGFP-HAC loss were 
carried out in triplicate. The results were reproducible and the std were small (for example, Pt-ttpy: 
SD±0.9%; MST-312: SD±1.1%).  
 To study mitotic abnormalities induced by Pt-ttpy and MST-312 in the telomerase positive 
HT1080 and HCT116 and telomerase negative U2OS cell lines, we used much lower concentrations of 
the drugs as at the LC50 only very small numbers of mitotic cells were seen.  For these experiments, the 
cells were treated by noncytotoxic drugs concentrations as a dose based on published data and proven 
experimentally for our cell lines (see Supplementary Table S2).  
   
Calculation of the rate of spontaneous HAC loss and after compound treatment 
 
In our study, we determined the normal rate of spontaneous HAC mis-segregation (RNormal) in the host cell 











  ; where P0 is the percentage of EGFP(+) cells 
at the start of the experiment as determined by FACS. These cells were cultured under HAC selection 
conditions using blaticidin. PNormal is the percentage EGFP(+) cells after culturing without HAC selection 
(no blasticidin) for a duration of t1. In this study t1 was 14 days. n1 is the number of cell doublings that 
occurs during culturing without blasticidin selection. The doubling time of HT1080 under normal growth 
conditions is approximately 18 hours. The number of cell divisions (n) is calculated by (t / host cell 
doubling time). 
Once (RNormal) was obtained, the rate of HAC loss induced by drug treatment (RDrug) is determined 
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 . As before, P0 represents the percentage of 
EGFP(+) cells at the start of the experiment, cultured under HAC selection condition. PTreated is the 
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percentage of EGFP(+) cells at the end of the drug treatment experiment with a duration of (t2 + t3), where 
t2 is the duration of drug treatment and t3 is the duration of culturing after the drug is removed. (t2 + t3) 
was 14 days in this study. n2 is the number of cell doublings that occurs during drug treatment, while n3 is 
the number of cell doublings that occurs during the culturing without selection after drug treatment. 
In the present study, the duration of most drug treatments was less than the duration of a single cell cycle 
of HT1080 (t2 <18 hr). We made the assumption that any significant increase in HAC loss occurs only 
during the first mitotic division after wash-out of the drug (n2 = 1). Thus n3 = (14d / 18hr - 1). The 
algorithm we used is valid between the ranges R = 0 to 1. R values large than 1 indicate that the 
assumptions made in this model are incorrect. The assumption of synchronous growth in the model means 
that the estimated mis-segregation rate is lower than real values. As the spontaneous rate of HAC mis-
segregation (RNormal) was found to be low, this algorithm is relatively insensitive to the number of cell 
divisions that occurs post drug treatment (12).  
 
Cell viability test for measuring HAC loss in response to drug treatment 
 
For each compound LC50 was determined using a MTS tetrazolium cell viability assay according to the 
manufacturer’s instructions (CellTiter 96 AQueous Assay reagent; Promega). Briefly, the CellTiter 96 
AQueous One Solution Reagent was added to each well and incubated at 37°C for 3 hr. Cell proliferation 
was determined by measuring the absorbance at 490 nm using a microtiter plate reader (Molecular 
Devices, Sunnyvale, CA). The LC50 was obtained from the MTS viability curves using GraphPad Prism 
5. Experiments were carried out in triplicate.  
 
FISH analysis for the circular HAC  
 
The presence of the circular HAC in an autonomous form was confirmed by FISH analysis as previously 
described (22). HT1080 cells containing the HAC were grown in DMEM medium to 70-80% confluence. 
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Metaphase cells were obtained by adding colcemid (Gibco) to a final concentration of 0.05 μg/ml and 
incubating overnight. Media was aspirated, and the plate washed with 1x PBS. Cells were detached from 
the plate by 0.25% Trypsin, washed off with DMEM, pelleted and resuspended in 10 ml of 50 mM KCl 
hypotonic solution for 30 min at 37°C. Cells were fixed by three washes of fixative solution (75% acetic 
acid, 25% methanol). Between washes, cells were pelleted by centrifugation at 900 rpm for 4 min. 
Metaphase cells were evenly spread on a microscope slide and the fixative solution evaporated over 
boiling water. Dry slides were rehydrated with 1xPBS for 15 min and fixed in 4% formaldehyde-1x PBS 
for 2 min, followed by three 5 min 1xPBS washes and ethanol series dehydration. PNA (peptide nucleic 
acid) labeled probes used were telomere (CCCTAA)3-Cy3) (PerSeptive Biosystems, Inc.) and tetO-
alphoid array (FITC-OO-ACCACTCCCTATCAG) (Panagene, South Korea). Ten nanomol of each PNA 
probe was mixed with hybridization buffer and applied to the slide, followed by denaturation at 800C for 
3 min. Slides were hybridized for 2 hours at room temperature in the dark. Slides were washed twice in 
70% formamide, 10 mM Tris pH 7.2, 0.1% BSA, followed by three washes with 1xTBS, 0.08% Tween-
20. Slides were dehydrated gradually with a series of 70%, 90% and 100% ethanol washes and mounted 
(Vectorshield with DAPI). Images were captured using a Zeiss Microscope (Axiophot) equipped with a 
cooled-charge-coupled device (CCD) camera (Cool SNAP HQ, Photometric) and analyzed by IP lab 
software (Signal Analytics). The PNA-DNA hybrid probes demonstrated a high hybridization efficiency 
and staining. 
 
FISH analysis for the linear HAC 
 
Slides with metaphases were rehydrated with 1xPBS for 15 min at RT, fixed with 4% Paraformaldehyde 
(PFA), prepared on 1xPBS, for 2 min and washed 3 times with 1xPBS for 5 min. Then slides were 
gradually dehydrated at RT for 5 min each: 70% EtOH, 90% EtOH, 100% EtOH and then dried. 
Hybridization mix (10 mM Tris-HCl, pH7.4; 70% Formamide; 5% Dextran sulfate; 10 ng PNA-TRITC-
telomere (Panagen); 10 ng Biotin-labeled-EGFF sequence in the linear HAC was applied onto each 
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dehydrated slide in 20 uL of volume and covered with a coverslip.  Slides were next denaturated at 80°C 
on heating table for 3 min in the dark and then incubated 2-6 hours at RT in the dark. Cover glasses were 
then removed and slides washed 2 times in washing Solution I (70% Formamide/10 mM Tris-HCl pH 
7.4/0.1% BSA) for 15 min, 3 times in washing Solution II (20 mM Tris-HCl pH 7.4; 136 mM NaCl; 
0.08% Tween) for 5 min, and briefly rinsed once in PBS. For biotin detection, 60 L of Avidin-FITC 
solution (Sigma) was applied, covered with a 24x60 mm coverslip and incubated for 40 min at 37C in a 
moist chamber in the dark. To amplify the signal, slides were washed in 4x SSC/0.1% Tween-20 three 
times for 2 min at 45C, after which 60 l of anti-avidin solution (Sigma, 1:200 dilution in 4xSSC/0.1 
Tween-20) was applied, covered with 24x60 mm coverslip and incubated for 40 min at 37C in a moist 
chamber in the dark. Next, a second round of detection was performed in the same manner. Then slides 
were gradually dehydrated at RT for 5 min each: 70% EtOH, 90% EtOH, 100% EtOH and dried. Slides 
were mounted in Vectashield mounting media, containing DAPI (Vector Laboratories). Images were 
captured and analyzed using a DeltaVision microscopy imaging system and software in the CRC, LRBGE 




For Figures 1 and 8: treated cells were fixed in 4% PFA in PBS for 15 min at RT. Cells were rinsed two 
times quickly with PBS followed by incubation for 15 min with a last PBS wash at RT. 200 ml of 5% 
BSA in PBS-TT (PBS containing 0.5% Tween-20, 0.1% Triton X-100) were added to the washed cells 
and incubated for 30 min in a humid chamber. Cells were rinsed once in PBS-T (PBS, containing 0.1% 
Tween-20) for 5 min. 200 µl of γHistone2AX antibody (Abcam, Cat. No. # 05-636, mouse origin, 
dilution 1:500) and TRF2 antibody (Santa Cruz, Cat. No. # sc-9143, rabbit origin, dilution 1:200) in 1% 
BSA in PBS-TT were added for 2 hr at RT in the humid chamber. The samples were washed three times 
for 5 min in PBS-T. 200 µl of secondary antibodies (goat-anti-mouse Alexa 488, dilution 1:500, Life 
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Technology A11029; goat-anti-rabbit Alexa 555, dilution 1:500, Life Technology A21428) were applied 
at RT in the humid chamber for 1 hr. The samples were washed three times in PBS-T for 5 min. The 
samples were counterstained with DAPI and mounted with mounting media (ProLong™ Diamond 
Antifade Mountant with DAPI, Life Technology, P36962). Samples were analyzed using 
DeltaVision Microscopic System at the CRC, LRBGE Fluorescence Imaging Facility (NIH). For each 
compound, at least 120 nuclei were analyzed. 
For Figures 4, 5, 6, 7 and Supplementary Figures S5, S6, S7, S8, S9, S10, S11, S12, S13 and S14: 
after drug treatment, the cells were rinsed in PBS and then fixed in 4% paraformaldehyde in PBS. Cells 
were then permeabilised and blocked before incubation with primary antibodies. Primary antibodies used 
in this study include: mouse monoclonal anti α-tubulin (SIGMA), rabbit polyclonal anti-Survivin 
(NOVUS), rabbit polyclonal anti-Aurora B (Abcam), rabbit polyclonal anti-INCENP (Cell Signalling), 
mouse monoclonal antibody anti-Borealin (MBL), rabbit polyclonal anti-phosphorylated Histone3 Ser10 
(Millipore), mouse monoclonal anti-LAP2 (BD Biosciences), mouse monoclonal anti-phosphorylated  
Gamma H2A.X Ser139 (Abcam). Fluorophore-conjugated secondary antibodies were purchased from 
Jackson Immunoresearch. Samples were counterstained with DAPI and mounted in Vectashield. 
Microscope images were acquired on a DeltaVision Core system (Applied Precision) using an inverted 
Olympus IX-71 stand, with an Olympus UPlanSApo ×100 oil immersion objective [numerical aperture 
(NA) 1.4] and a LED light source. The camera (Photometrics Cool Snap HQ), shutter and stage were 
controlled by SoftWorx 5.5.0 (Applied Precision). Z-series were collected with a spacing of 0.2 μm, and 
image stacks were subsequently deconvolved using SoftWorx. Projected Z-sections were exported as 
TIFF files into Adobe Photoshop. 
 
Trichostatin A treatment 
 
Aliquots of ∼2.4 × 106 HT1080 cells carrying a circular alphoidtetO-HAC or a linear 21ΔqHAC both 
carrying EGFP were incubated in 2 ml of non-selective medium containing 100 ng/ml of Trichostatin A 
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For Western blot analysis, HT1080 lysates were subjected to electrophoresis on SDS-PAGE followed by 
transfer to Hybond membrane (Amersham Biosciences, NJ) according to the manufacturer’s instructions. 
Concentrations for blot analysis of anti-hTERT as well as secondary antibodies varied according to the 
manufacturer’s recommendation (Santa Cruz Biotehnology, Jackson ImmunoResearch, West Grove, PA).  




Experimental design for the identification of compounds specifically targeting telomeres and 
telomerase  
 
To identify compounds specifically targeting telomeres or telomerase, we developed an assay based on 
the use of two different human artificial chromosomes (HACs) – Figure 1. Both HACs are of 
approximately the same size (5 Mb) (23,24) but one of them is circular while the other is linear and has 
telomeres (Fig. 1A). Both HACs have functional kinetochores and are maintained as non-essential extra 
chromosomes, replicating and segregating like normal chromosomes in human cells. The rate of 
spontaneous loss (no treatment) was approximately the same for circular and linear HACs (loss rate = 
0.0024 and 0.0054, correspondingly). Both HACs carry the same EGFP (enhanced green fluorescence 
protein) transgene flanked by HS4 insulators that is stably expressed from the HACs. Cells that inherit the 
HAC display green fluorescence, while cells that lack it do not (Fig. 1B). After drug treatment, there are 
two expected outcomes: either there is no change in the percentage of EGFP-expressing cells (no effect 
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on HAC stability) or, if the compound induces chromosome segregation errors, there is an increase in the 
percentage of EGFP-negative cells (Fig. 1C). Control untreated cells containing either of these HACs 
show uniform green fluorescence. The actual percentage of cells carrying EGFP-HAC can be measured 
by FACS as previously described (18). 
The circular HAC used in our experiments is the alphoidtetO-HAC (15), which was engineered 
from a synthetic alphoid DNA array and was previously used to screen for drugs inducing chromosome 
instability (CIN) (18). The linear 21ΔqHAC was engineered by truncation of human chromosome 21 
using telomere containing plasmids (25). These HACs possess several useful and similar features: 1) they 
have a well-defined architecture (24,26); 2) they are present episomally, independently of the host 
chromosomes (13,14,23,27); 3) they are mitotically stable both in human cell lines and mice, but slightly 
less stable than natural human chromosomes, so that the system is sensitized (15,25,28-32); 4) EGFP 
expression from the HACs is stable  (33,34). No epigenetic silencing of EGFP was observed after 24 
months of continuous culturing of HAC-containing human HT1080 cells under blasticidin selection 
(33,34). Importantly for these experiments, HT1080 cells containing either the linear or circular HAC 
express human telomerase (hTERT) (Supplementary Figure S1). The experimental design comparing 
segregation fidelity of the circular and linear HACs reported here can be used not only to identify new 
compounds that specifically target telomeres or telomerase but also to rank those compounds according to 
their effect on the segregation of the linear HAC 
 
Compounds used in this study 
 
Initially we chose several groups of known anti-telomerase compounds. They included antisense 
oligonucleotides that target the RNA template of human telomerase (hTERT), a set of small molecule 
telomerase inhibitors that block the catalytic activity of the enzyme and compounds that block the access 
of telomerase to telomeres, among them G-quadruplex (G4) stabilizers. These compounds can bind to and 
stabilize the secondary DNA structures formed by genomic G-rich sequences such as telomeres. This 
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blocks telomerase access to telomeres, uncapping them and mimicking ssDNA overhang exposure. Thus, 
these agents are good candidates to increase chromosome instability. In this study, we used a panel of G-
quadruplex stabilizers belonging to various chemical classes: the bisquinolinium series comprised of 
Phen-DC3, Phen-DC6, PDC and their functional derivatives Phen-DC3-C4Bn, PDC-C4Bn, Phen-DC3 
Bisalk1; the styryl derivatives series PhenDV, PhenDV-An and Bisphenyl-Vpy; the metal complexes 
series CuBisQ, Pt-ttpy and Cu-ttpy; and a series of benchmark compounds of diverse structures MMQ3, 
TrisQ, TMPyP4, BRACO19, PIPER and Pyridostatin (Supplementary Table S1). A negative control CN1 
that has no G4-binding ability was also included in the analysis. The compounds effecting telomerase 
were GRN163L, BIBR1532, MST-312 and 6-Thio-dG (Supplementary Table S1). Chemical structures of 
most of the compounds have been published previously (see references in Supplementary Table S1). The 
structures and synthesis of four G4-stabilizers developed recently in our group, Phen-DC3 Bisalk1, Phen-
DC3C4Bn, PhenDMA and Bisphenyl-VPy, are shown in Supplementary Figure S2A-D. The structures of 
previously developed components, Pt-ttpy and Cu-ttpy, are shown in Supplementary Figure S2E-F. 
We previously demonstrated in other screens that the highest rate of drug-induced HAC loss 
occurs at the compound’s LC50 (12). Higher concentrations of drugs killed more cells but did not 
increase the rate of HAC loss (12,18). In contrast, treatment at lower concentrations induced either no or 
lower frequency HAC loss. Because the LC50 provides a useful parameter to normalize the results from 
different drugs/compounds we determined LC50 values for all compounds, except the specific telomerase 
inhibitor GRN163L, i.e. conditions under which HT1080 cell viability was around 50%. For GRN163L 
we could not determine the LC50 because even the highest concentration of this drug did not lead to 
detectable cell death. Thus, for GRN163L we used concentrations recommended in the literature (10,35). 
The complete list of compounds used in this work is presented in Supplementary Table S1. The results of 
LC50 determinations are shown in Supplementary Table S2.  
 
Verification of the system: effect of GRN163L on mitotic stability of circular and linear HACs 
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Drugs that induce CIN via mechanisms that do not involve telomeres/telomerase should affect HAC 
stability independently of the presence or absence of telomeres. In our previous work using a circular 
HAC to rank a set of anticancer drugs according to their effect on chromosome instability (18) significant 
effects were observed after treatment with Taxol (microtubule stabilizing agent), LMP400 and 
Camptothecin [specific inhibitors of topoisomerase 1 (TOP1)], Olaparib (PARP inhibitor), Cisplatin and 
Gemcitabine (DNA damage compounds). In the present control experiments, the rate of loss in response 
to drug treatment was indistinguishable between linear and circular HACs (Supplementary Figure S3A). 
Notably no increase in green cells was observed when the histone deacetylase inhibitor TSA (trichostatin 
A) was added to the culture (Supplementary Figure S3B), indicating that these inhibitors do not induce 
transgene silencing but rather induces a high rate of linear HAC loss. 
 We next investigated the effect on the stability of circular vs linear HAC of one of the most 
specific telomerase inhibitors described to date, imetelstat or GRN163L. This compound consists of a 13-
mer oligonucleotide N3’-P5’ thio-phosphoramidate covalently attached to a C16 (palmitoyl) lipid moiety. 
It directly binds to the RNA component of telomerase (hTERT) with very high affinity in the active site 
of the telomerase enzyme (10,36). GRN163L has been shown to inhibit telomerase in a wide range of 
human solid tumor cells, including lung, breast, prostate liver, brain and also in hematological 
malignancies, including multiple myeloma and lymphoma (10,35).  
Cells carrying either a linear or a circular HAC, were treated with increasing concentrations of 
GRN163L. Treatments were carried out for 3 days, as shorter treatment times do not result in a significant 
shortage of the telomeres and chromosome instability (10,35). As expected, treatment with increasing 
concentrations of GRN163L resulted in a specific concentration-dependent destabilization of the linear 
HAC (Fig. 2A). Importantly, the mitotic stability of the circular HAC was not affected under the same 
conditions. This proof of principle experiment indicated that our dual-HAC system allows to identify new 
compounds specifically targeting telomeres or telomerase. 
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6-Thio-dG and MST-312 have the highest effects on the linear HAC mis-segregation rate 
 
Four known telomerase and telomere inhibitors, 6-Thio-dG (36), BIBR1532 (37), GRN163L (10,35), and 
MST-312 (38), were included in the analysis. The LC50 of these compounds in HT1080 cells is shown in 
Supplementary Table S2. HT1080 cells carrying either a linear or a circular EGFP-HAC were treated with 
each compound overnight. Figure 2B summarizes the results on HAC stability. Treatment with 
BIBR1532 increased the rate of loss of the linear HAC approximately 15 times compared to control 
untreated cells. The two other inhibitors tested, 6-Thio-dG and MST-312, also resulted in a significant 
increase of the rate of loss of the linear HAC, with the highest effect observed after treatment with MST-
312 (approximately a 40-fold increase). Interestingly, this inhibitor also affected the stability of the 
circular HAC (approximately a 15-fold increase). Overnight treatment by GRN163L at 50 M only 
slightly and equally affected stability of linear and circular HACs despite the fact that much lower 
concentrations of the same compound (1 M and 10 M) but longer treatment (3 days) specifically and 
significantly increased the rate of loss of only the linear HAC (Fig. 2A).  
 To summarize, the dual-HAC assay allowed us to rank the strongest and most specific inhibitors 
of telomerase and telomeres according to their effects on chromosome stability. Two inhibitors in 
particular, 6-Thio-dG and MST-312, caused a significant increase of the rate of loss of the linear HAC 
after one day of treatment. 6-Thio-dG appeared to be the best among the compounds analyzed, as it 
exhibited both the highest and most specific effect on linear HAC stability (Fig. 2B).  
 
Analysis of G-quadruplex ligands revealed two compounds, Pt-ttpy and Cu-ttpy, with significant 
effects on mitotic transmission of the linear HAC 
 
Next, we investigated how structurally diverse G-quadruplex ligands affect chromosome stability. 
HT1080 cells carrying the circular or the linear EGFP-HAC were treated overnight with 19 different G4 
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ligands: Phen-DC3, Phen-DC6, TrisQ, Phen-DC3C4Bn, Phen-DV-Py, Phen-DV-An, CN 1, Phen-DC3 
Bisalk1, PDC, PDC C4Bn, CuBisQ, Pt-ttpy, Cu-ttpy, Bisphenyl-Vpy, MMQ3, TMPyP4, BRACO19, 
PIPER and Pyridostatin. (LC50 values of these compounds are shown in Supplementary Table S2.) 
Figure 2C illustrates the effect of these compounds on the rate of HAC loss.  As seen, no significant 
increase in loss of the circular HAC was detected with most of the analyzed compounds. Eight 
compounds, PDC C4Bn, TrisQ, Phen-DC3, BRACO19, Pyridostatin, Phen-DC6, Cu-ttpy, and Pt-ttpy, 
increased the rate of linear HAC loss.  After treatment by Cu-ttpy and Pt-ttpy this rate was almost 70- and 
90-fold higher compared to that observed in control untreated cells (Fig. 2C).   
 In summary, our dual-HAC assay allowed us to rank 19 G-quadruplex ligands according to their 
effects on chromosome stability. The two compounds, Cu-ttpy and Pt-ttpy, exhibited the highest effects 
on stability of the linear but not the circular HAC. This makes them potentially interesting candidates for 
future development as therapeutic agents, and therefore we decided to investigate further their mechanism 
of action in cancer cells. 
 
Pt-ttpy and MST-312 treatments produce defects in mitosis  
 
Pt-ttpy and Cu-ttpy are metallo-organic complexes of a similar structure containing a tolylterpyridine 
moiety (ttpy) coordinated with either copper (Cu 2+) or platinum (Pt 2+) cation (Supplementary Figure 
S2E-F) (20,21). To explore the mechanism by which they disturb chromosome transmission, we have 
performed the first detailed analysis of the effect of Pt-ttpy in mitosis. In parallel, we analyzed the effect 
of the telomerase inhibitor MST-312, a compound that also induces a high rate of instability in our assay 
for the linear HAC (Fig. 2B). In these experiments, the cells were treated by noncytotoxic drugs 
concentrations as a dose based on published data and proven experimentally for our cell lines (see 
Supplementary Table S2). Preliminary studies of MST-312 have revealed some mitotic abnormalities, but 
still many questions remained unanswered in this regard (38-40). To rule out cell-line specific 
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phenotypes, all experiments were carried out in two different telomerase-expressing cell lines, HT1080 
(Supplementary Figure S1) and HCT116 (41). 
  Pt-ttpy- and MST-312-treated HT1080 and HCT116 cells were stained with antibodies against 
phosphorylated HistoneH3 (Ser10) – a mitosis-specific modification- and against α-tubulin to visualise 
the mitotic spindles (Fig. 3A-D and Fig. 4A-H; Supplementary Figures S4A-F and S5A-I). MST-312-
treatment of HT1080 cells caused a significant decrease of the mitotic index (the fraction of cells in a 
population undergoing mitosis) (Fig. 3A), associated with a significant increase in the proportion of 
mitotic cells in prometaphase and a decrease of the proportion of cells in cytokinesis (Fig. 3B). Further 
quantification revealed a significant increase in mitotic abnormalities in MST-312-treated cells (Fig. 3C). 
These included defects in chromosome alignment (Fig. 4C-D) and chromatin bridges in late mitosis (Fig. 
4G). Quantification of chromatin bridges is of special interest because they can form when telomeres of 
sister chromatids fuse and fail to completely segregate into the respective daughter cells (42). In contrast, 
Pt-ttpy treatment of HT1080 cells caused no significant decrease in the mitotic index (Fig. 3A) or total 
percentage of mitotic abnormalities (Fig. 3C). Notably, Pt-ttpy also induced chromatin bridges (Fig. 4H). 
 HTC116-treated cells showed similar phenotypes to HT1080-treated cells (Supplementary 
Figures S4A-F and S5A-I) but in addition we observed an increased frequency of spindle pole defects 
(Supplementary Figure S5E-F). It thus appears that the spindle phenotypes are specific to the HCT116 
cell line. We have observed similar effects previously in this cell line when studying the effect of other 
drugs treatments (Carmena, unpublished results). In contrast, the MST-312-induced chromosome 
misalignment phenotype was observed in both cell lines and is consistent with the increase in the 
frequency of prometaphases. 
 




The defects in chromosome alignment shown by the MST-312-treated cells are reminiscent of the 
phenotypes caused by defects in CPC function. Aurora B kinase (the enzymatically active component of 
the CPC) destabilizes incorrect kinetochore-microtubule attachments and, therefore, promotes correct and 
timely chromosome bi-orientation (43,44).  
 Levels and localization of the CPC components were analysed in HT1080 (Fig. 5) and HCT116 
cells (Supplemental Figure S6). Levels of Survivin were reduced in MST-312-treated cells and its 
localization was abnormal in early mitosis (Fig. 5A-D and Supplementary Figure S6A-C). Similar results 
were obtained when studying the distribution of the other CPC components, Borealin (Fig. 5A-D), 
INCENP and Aurora B kinase (Fig. 5E-H and Supplementary Figure S6D-E). To assess whether this had 
an effect on Aurora B activity, we stained MST-312-treated cells with an antibody against the activated 
form of the kinase (anti-Aurora B phospho-T232) (Supplementary Figure S7A-H). This revealed that the 
level of the active Aurora B was reduced in early mitosis. Thus, MST-312 affects - either directly or 
indirectly - the function of Aurora B kinase in both HT1080 and HCT116 cells. This is likely to be the 
cause of the defects in chromosome alignment and consequent delay in prometaphase observed in drug-
treated cells.  
 Pt-ttpy treatment did not result in chromosome alignment defects as described above (Fig. 4; 
Supplementary Figure S5). As known, MST-312 inhibits telomerase activity (45) while Pt-ttpy binds to 
G-quadruplexes, hindering telomerase access to telomeres (but not affecting telomerase activity) (20,21). 
Thus, one possible explanation is that telomerase activity is somehow required for Aurora B/CPC 
function, so this would not be altered after treatment with Pt-ttpy, as telomerase remains active. Another 
possible explanation is that inhibition of Aurora B kinase is an off-target effect of MST-312.  
To test this possibility, we used U2OS, an ALT cell line that does not express telomerase (46). 
MST-312-treated U2OS cells showed the chromosome misalignment phenotype [Supplementary Figures 
S8A-F (DMSO); Supplementary Figures S8A’-F’ (MST-312) and Supplementary Figure S9A-B] 
suggesting that indeed Aurora B kinase inhibition is likely an off-target, telomerase-independent effect of 
MST-312. This effect possibly contributed to the elevated rate of chromosome instability detected in our 
 20 
original screen and could also explain why this compound has also an effect on segregation of the circular 
HAC. (Fig. 2A). 
 
Pt-ttpy and MST-312 both induce chromatin bridges and UFBs (Ultrafine Bridges) in mitosis 
 
Our analysis of mitosis in drug-treated cells revealed the presence of chromatin bridges in late mitosis and 
cytokinesis (see Fig. 4 and Supplementary Figure S5). To carry out a detailed quantification of the 
frequency of chromosome bridges in late mitosis in HT1080 and HCT116 cells treated with Pt-ttpy and 
MST-312, we used an antibody against Survivin and LAP2, a nuclear envelope protein that decorates 
chromatin bridges. This works because during late anaphase and telophase LAP2 and other nuclear 
envelope components decorate the decondensing chromatin while it is still in the process of moving 
polewards. With LAP2 antibody, bridges are readily visible, even when they are too fine to be visualised 
by DAPI staining (Fig. 6A-C and Supplementary Figure S10A-E). These experiments revealed that our 
previous analysis had underestimated the number of chromatin bridges in late mitosis (anaphase to 
cytokinesis). As described above, we observed a statistically significant increase in the percentage of late 
mitotic cells showing chromatin bridges in cells treated with either Pt-ttpy or MST-312 (Fig. 3D; 
Supplementary Figure S4F). A similar analysis in telomerase-negative U2OS cells showed no significant 
increase in chromatin bridges (Supplementary Figure S9B). We, therefore, concluded that this phenotype 
is likely to be a consequence of the disruption of telomerase activity and/or telomere function. 
 We also analysed the formation of Ultrafine Bridges (UFBs) following Pt-ttpy and MST-312 
treatment. HCT116-treated cells (Supplementary Figure S11A-C) were stained with antibodies against 
Blooms Syndrome protein (BLM) and against phosphorylated histone H2AX (γHistone2AX). UFBs were 
increased in anaphase/telophase after either treatment (Supplementary Figures S11D). The similar results  
were obtained in HT1080-treated cells (Supplementary Figure S12A-D). Importantly, no significant 




Pt-ttpy-treated cells show an increased number of double-stranded breaks (DSBs) that colocalise 
with telomeric markers  
 
To begin to investigate the mechanism(s) by which drug treatment resulted in chromosome loss, we 
stained double-stranded breaks (DSBs) in interphase drug-treated cells with an antibody against 
phosphorylated γH2AX. The number of DSBs was increased after treatment with either Pt-ttpy or MST-
312 (Supplementary Figure S14A-F). To determine whether DSBs are associated with telomeric 
sequences, we examined co-localization of γH2AX foci with the telomeric protein TRF2 (telomeric repeat 
binding factor 2) (Fig. 7A). Because the nucleoside analog 6-Thio-dG is known to be incorporated into de 
novo-synthesized telomeres and cause DNA breaks (36,47) it was used as a control in this experiment. In 
addition, we included in this analysis Cu-ttpy, a compound with a structure similar to Pt-ttpy. 
Immunostaining with antibodies against TRF2 and γH2AX was carried out every 24 hours for 3 days (see 
Materials and Methods). A statistically significant co-localization of γH2AX foci and TRF2 protein was 
observed at day 3 for 6-Thio-dG (4.5%), Pt-ttpy (6.2%), and Cu-ttpy (9%) (Fig. 7B). Note that telomeres 
represent only ~1/6,000 of the total human genome. Therefore, if the γH2AX foci were distributed evenly 
along the chromosomes, at telomeres we would expect to observe only 0.016% colocalization. As shown 
above, Pt-ttpy also induces additional DSBs outside of telomeres. This is consistent with the description 
of non-telomeric targets for G4-stabilizers in the promoter sequences of some oncogenes and other G-rich 
genomic regions (21,48,49). G-quadruplex-forming genomic sequences, similar to telomeres, represent 
natural replication fork barriers. 
 To summarize all of the above experiments, chromosome loss after Pt-ttpy treatment may be due 
to the induction of DSBs that are predominantly localized at telomeres. Such telomere damage could 





As telomerase is constitutively expressed in many human cancers, telomerase-targeting therapy has been 
considered to be a potentially promising approach for cancer treatment (6,50-52). However, a limited 
number of chemical compounds that target telomerase or telomeres have been identified and only some of 
these are in clinical trials. Moreover, protocols that allow quantitative comparison of the efficiency and 
specificity of these compounds were lacking. 
 To address this point, we developed a novel assay allowing comparison of libraries of compounds 
for their ability to induce telomere dysfunction leading to chromosome loss. Even transient telomere 
dysfunction can induce chromosomal instability (CIN) in human cells (53). Therefore, the activity of each 
compound can be evaluated based on its effect on CIN. To quantify this effect, we used two isogenic cell 
lines with linear and circular HACs carrying the EGFP color marker. Specific destabilization of the linear 
HAC (containing telomeres) in response to drug treatment is consistent with specific targeting of 
telomeres or telomerase. Conversely, destabilization of both linear and circular HACs suggests that a 
compound has off-target effects in addition to its effect on telomerase. We initially verified our dual-HAC 
system using GRN163L, a well-characterized and highly specific inhibitor of telomerase. We found that 
this experimental design can be used to rank known and newly developed compounds targeting 
telomerase or telomeres.  
 In this study, the dual-HAC assay was applied to analyze a set of known and newly developed 
compounds targeting telomerase or telomeres, including G4 ligands. For each drug, the rate of HAC loss 
was quantified and within each analyzed group, the compounds were ranked according to their HAC-
destabilizing potency. Analysis of four well-known telomerase inhibitors revealed the nucleoside 
analogue 6-Thio-dG (36,47) as the highest and the most specific drug with respect to its effect on the 
linear HAC stability in this assay. It was quite unexpected that this drug, which may be incorporated into 
DNA strands during replication, induced a more specific effect on linear HAC stability than other 
analyzed telomerase inhibitors such as MST-312. Furthermore, our studies of MST-312 action in ALT 
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cells that lack active telomerase suggested that this drug has other targets that are important for 
chromosome segregation, possibly including the Chromosomal Passenger Complex. 
 Ranking of 19 G-quadruplex (G4) ligands revealed that two recently developed compounds, Cu-
ttpy and Pt-ttpy, exhibited the highest rate of linear HAC mis-segregation, i.e. a 70 and 90-fold increase 
compared to the controls, respectively. Our results suggest that these two compounds or their derivatives 
may be useful for a new telomere-addressed anticancer approach, by exacerbating the CIN phenotype in 
cancer cells. One possible mechanism that might explain chromosome loss after Pt-ttpy and Cu-ttpy 
treatment is an increased number of double-stranded breaks (DSBs) at or near telomeres. Such telomere 
damage may lead to the formation of chromosome bridges and UFBs that we observed in 
anaphase/telophase and could ultimately result in chromosome mis-segregation. Alternatively, treatment 
with these agents might interfere with telomere replication, leading to UFBs formation and subsequent 
DNA damage. It is worth noting that we cannot exclude additional mechaisms of action for these G4 
ligands such as transcriptional inactivation of genes important for chromosome segregation or induction 
of chromosomal DSBs as previously was described for other G4 stabilizers (21,48,49). Indeed, other 
authors have reported that non-specific induction of DNA damage enhances telomeric dysfunction 
induced by G quadruplex-stabilizing agents (54). 
 Among other possible applications of the dual-HAC system described here is analysis of the 
genetic control of the alternative lengthening of telomeres (ALT) pathway in telomerase-negative cells.  
The ALT pathway is specific for cancer cells (7). Until now the development of ALT-targeted therapy has 
been challenging as the identification of proteins specific to ALT has proven elusive: all enzymes thus far 
shown to play any role in ALT are also critical for normal cellular functions. Transfer of circular and 
linear HACs into telomerase-negative cells might be used to identify genes or compounds that disturb the 
ALT pathway (for example, by siRNA gene depletion).  
To summarize, this study describes a novel approach that may be applied to the quantitative 
analysis of known and novel compounds used in cancer therapy to determine their ability and potency to 
specifically target telomeres or telomerase. The identification of compounds that selectively inactivate 
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telomere replication and interfere with cell proliferation could lay the foundation for new treatment 
strategies for cancer. 
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Figure 1. Scheme of an assay for measuring chromosome instability (CIN) based on the use of a linear 
HAC versus a circular HAC, both containing the EGFP transgene. A, FISH analysis of the HACs in 
HT1080 cells. The circular HAC was visualized using PNA probes for telomeres and for the vector part 
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of the HAC as previously described (22,24). The linear HAC was visualized using the PNA probes 
designed in this work (see Materials and Methods for details). Chromosomal DNA was counterstained 
with DAPI. The HACs are indicated by arrowhead. B, Fluorescence images of cells carrying the EGFP-
containing HACs. C, Scheme of an assay for measuring CIN based on the use of linear versus circular 
HACs, both containing the EGFP transgene. Cells that inherit any of these HACs display green 
fluorescence, while cells that lack them do not. Because both HACs are pretty stable during cell division, 
it is expected that the control cells should display uniform green fluorescence while there will be a 
mixture of EGFP positive and negative cells in the drug-treated population if the drug is specific to 
telomeres or telomerase (a linear HAC). The actual percentage of cells carrying EGFP-HAC can be 
measured by FACS as previously described (18).  
 
Figure 2. Effect of telomerase and telomeres inhibitors on a linear and a circular HAC mis-segregation 
rate. A, Effect of the telomerase inhibitor GRN163L, that directly binds with high affinity and specificity 
to the RNA component of telomerase (hTERT), on the stability of a linear and a circular HAC. HT1080 
cells containing either a linear or a circular HAC were treated by GRN163L at concentrations of 1 M, 10 
M or 50 M for 3 days. A specific concentration-dependent destabilization of the linear HAC was 
observed. B, Effect of telomerase and telomeres inhibitors, 6-Thio-dG, BIBR1532, GRN163L and MST-
312, on a linear versus a circular HAC mis-segregation rate. HT1080 cells containing either a linear or a 
circular HAC were treated with the compounds at the concentrations corresponding to their LC50 
(Supplementary Table S2) overnight. MST-312 was the strongest CIN inducer (approximately 40-fold 
increase of loss rate of a linear HAC). C, Effect of 19 G-Quadruplex ligands that may recognize telomere 
repeats on a linear and a circular HAC mis-segregation rate. The highest rate of the linear HAC loss was 
observed after treatment by Cu-ttpy and Pt-ttpy (almost 70- and 90-fold increase compared to the control, 
correspondingly). *stands for <0.001 (done by t-test). ** stands for p<0.005 (done by t-test). 
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Figure 3. Quantification of defects in mitosis upon MST-312 and Pt-ttpy treatment of HT1080 cells. A, 
Mitotic index (a ratio between the number of cells in a population undergoing mitosis to the total number 
of cells) upon MST-312 or Pt-ttpy treatment. Three independent experiments were performed for each 
drug and more than 1,000 cells (n) were screened. B, Distribution of cells in different stages of mitosis 
upon MST-312 or Pt-ttpy treatment. Three independent experiments were performed for each drug and 
more than 100 mitotic cells (n) were screened. C, The percentage of cells exhibiting defects in mitosis 
upon MST-312 or Pt-ttpy treatment. D, The percentage of cells presenting chromatin bridges in late 
mitosis upon MST-312 (5 μM, 10 μM) or Pt-ttpy (1 μM, 2 μM) treatment, quantified using LAP2 as a 
marker. In all experiments bars compare results of untreated cells (DMSO) with drug-treated cells. 
Relevant results from statistical analysis (t tests) are shown; error bars correspond to SD; N.S.= not 
significant. 
  
Figure 4. Analysis of mitotic phenotypes induced by MST-312 and Pt-ttpy treatment of HT1080 cells. 
Cells in different stages of mitosis were stained with antibodies against phosphorylated HistoneH3 
(Ser10) –a mitotic marker (in red) and α-tubulin (in green). A-B, and E-F, DMSO-treated control cells.  
C-D, MST-312-treated cells show chromosome alignment defects. Red arrows point at uncongressed 
chromosomes. G-H, Chromatin bridges appear in both MST-312- and Pt-ttpy-treated cells. Red/blue 
arrows point at chromatin bridges. 
 
Figure 5. Analysis of the level and localization of the Chromosomal Passenger Complex (CPC) in early 
mitosis in MST-312-treated HT1080 cells. A-D, Cells were stained with antibodies against Survivin (in 
red) and Borealin (in green). Localization of Survivin/Borealin in (A-B) control cells (DMSO) and (C-D) 
MST-312-treated cells in early mitosis. Red arrows point to examples where the proteins are dispersed 
along chromatin in treated cells. E-H, Cells were stained with antibodies against Aurora B (in red) and 
INCENP (in green). Localization of Aurora B and INCENP in (E-F) control cells (DMSO) and (G-H) 
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MST-312-treated cells in early mitosis. In drug-treated cells the levels of all four CPC components are 
lower and the proteins appears to be dispersed along chromosome arms (red/yellow arrows).  
 
Figure 6. MST-312 and Pt-ttpy treatment induces chromatin bridges in late mitosis in HT1080 cells. 
Cells in mitosis were stained with antibodies against LAP2 (in green) and α-Survivin (in red). A, Control 
cells (DMSO); B, MST-312-treated cells. C, Pt-ttpy-treated cells.  
 
Figure 7. Co-localization of γHistone2AX foci with the telomeric protein TRF2. A, Example of immuno-
staining of the cells treated with telomere-binding drugs 6-Thio-dG, Pt-ttpy and Cu-ttpy. Green signals – 
γHistone2AX staining. Red signals – TRF2 as a marker for telomeres localization. Accumulation of 
γHistone2AX foci occurred at day 3 in all cases. Co-localization of green and red signals indicates for the 
presence of double-strand breaks (DSBs) in the telomeric sequences (for details see Materials and 
Methods). B, A statistical effect of co-localization of γHistone2AX foci and TRF2 protein. A statistical 
effect was determined at day 3. Left panel shows the number of γHistone2AX foci in the cells treated 
with the drugs after 24, 48 and 72 hrs. Right panel shows the percentage of γHistone2AX foci present in 
the telomeric sequences. For each sample at least 120 nuclei were analyzed. Statistically significant 
(Fisher exact test: p-value; 2-tailed) results are indicated on the figure with square brackets. 
 
 
 







